![Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours](https://oncodaily.com/pub/uploads/2023/08/Andrea-Apolo-M.D-1-e1722793235555-1280x960.jpeg)
Photo from Andrea Apolo/X
Jul 5, 2024, 15:03
Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours
Andrea Apolo, Chief of Bladder Cancer Section Genitourinary Malignancies Branch Center for Cancer Research at NCI, shared on X:
“Cabozantinib/Nivolumab and Cabozantinib/Nivolumab/Ipilimumab have shown promising efficacy and safety in patients with metastatic urothelial carcinoma, metastatic renal cell carcinoma and rare GU tumors in a dose-escalation phase I study.”
Additional information.
Source: Andrea Apolo/X
Aug 29, 2024, 20:47